Henney highlights priorities for cash-strapped FDA as she embraces the letter and spirit of the law
This article was originally published in Clinica
The FDA's new commissioner, Jane Henney, said in her first major public speech in the US last week that she would focus on five top priorities: blood safety; tobacco regulation; food safety; implementation of the FDA Modernization Act of 1997(FDAMA); and promoting the agency's scientific base. In her brief remarks at the Food and Drug Law Institute's annual meeting she made no mention of the medical device industry.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.